the ultrasound picture of polycystic ovaries with half that number having clinical or biochemical signs of anovulation or androgen excess. PCOS is a familial condition. Most studies have focused exclusively on white populations. The prevalence of PCOS may be higher in other ethnic groups (e.g. South Asian immigrants to UK), 5 although further studies are needed.
Diagnosis of PCOS
The association of the clinical features of truncal obesity, oligo-or amenorrhoea and hirsutism with biochemical evidence of hyperandrogenaemia, elevated luteinising hormone and suppressed sex hormone-binding globulin (SHBG) and characteristic ovarian morphology on ultrasound has formed the basis of the diagnosis of PCOS for some years. However, biochemical abnormalities are seen in women with regular menstrual cycles and normal ovaries on ultrasound but who present with hirsutism or acne; and women of normal body mass who present with oligomenorrhoea will frequently exhibit biochemical and ultrasound signs of PCOS. 6, 7 The key underlying abnormality that leads to long-term health risk appears to be insulin resistancehyperinsulinaemia in the presence of normoglycaemia. 8, 9 Identification of patients with metabolic complications of PCOS should therefore focus on biochemical criteria to diagnose the syndrome, particularly hyperandrogenaemia, 10 together with an assessment of fasting glucose and insulin, lipids and triglycerides. 11 This should identify women with PCOS most at risk of long-term complications of their condition.
Young women diagnosed with PCOS should be informed of the possible longterm risks to health that are associated with their condition. They should be advised regarding weight and exercise.
Metabolic consequences of PCOS

PCOS and risk of type II diabetes
Insulin resistance in PCOS has been linked to later development of impaired glucose tolerance and type II diabetes. 12 Evidence from small long-term cohort studies, case-control studies and case series, points to a risk of type II diabetes in middle age of 10-20%, [12] [13] [14] with a higher rate of impaired glucose tolerance suggesting that further cases of diabetes will develop later. Increased body mass, particularly truncal obesity, and a strong family history of diabetes both increase the risk of developing type II diabetes in the presence of the polycystic ovary phenotype. 13 However, the frequency of type II diabetes is also increased in non-obese PCOS patients (body mass index less than 27 kg/m 2 ), 13, 14 suggesting that PCOS is an independent risk factor for type II diabetes in middle age.
Patients presenting with PCOS, particularly if they are obese, should be offered measurement of fasting blood glucose and urinalysis for glycosuria. Abnormal results should be investigated by a glucose tolerance test. Such patients are at increased risk of developing type II diabetes.
A sensible approach to ensure early detection of diabetes might be to offer screening to women with PCOS for glycosuria, and possibly measurement of fasting blood glucose, on a regular basis, perhaps annually.
PCOS and cardiovascular risk
Women with PCOS have not been found to have markedly higher than average mortality from cardiovascular disease, 15 despite their cardiovascular risk factors (obesity, hypertension, hyperandrogenism and hyperinsulinaemia). Women with PCOS frequently have abnormal lipid profiles, with raised triglycerides and total and low-density lipoprotein cholesterol. [16] [17] [18] The effect of PCOS on high-density lipoprotein cholesterol (HDL-C), however, is controversial. [15] [16] [17] evidence that the risk factors in PCOS women are elevated at an earlier age than among women without PCOS and therefore the risks of developing atherosclerotic conditions, hypertension and myocardial infarction are greater.
12,16,18
Measurement of fasting cholesterol, lipids and triglycerides should be offered to patients with PCOS, since early detection of abnormal levels might encourage improvement in diet and exercise.
PCOS and pregnancy
Women diagnosed as having PCOS before pregnancy have an increased risk of development of gestational diabetes. 19, 20 The risk is believed to be greatest in obese women with PCOS who required ovulation induction in order to conceive. Such patients should be screened for abnormal glucose tolerance in pregnancy and, if appropriate referred for antenatal management by an obstetrician with special interest in pregnancy and diabetes. A single, small, retrospective, matched-cohort study has suggested that metformin 2.25g taken throughout pregnancy reduces the chance of women with PCOS developing gestational diabetes. 21 However, metformin is not licensed in the UK for this indication and further larger prospective studies are necessary to provide adequate evidence of efficacy and safety of insulin-sensitising agents used in this context.
Women who have been diagnosed in pregnancy with gestational diabetes have been found to a high prevalence of PCOS on subsequent screening. This association is more common in women with raised body mass index.
22,23
Women who have been diagnosed as having PCOS before pregnancy (e.g. those requiring ovulation induction for conception) should be screened for gestational diabetes in early pregnancy, with referral to a specialised obstetric diabetic service if abnormalities are detected.
PCOS and cancer
It has been known for many years that severe oligo-and amenorrhoea in the presence of premenopausal levels of oestrogen can lead to endometrial hyperplasia and carcinoma. 24 In women with PCOS intervals between menstruation of more than three months may be associated with endometrial hyperplasia. 25 Regular induction of a withdrawal bleed with cyclical gestogens is advisable in oligomenorrhoeic women with PCOS. Those with persistently thickened endometrium when measured by transvaginal ultrasound should be advised to have an endometrial biopsy and/or hysteroscopy to rule our endometrial hyperplasia.
26
Oligo-and amenorrhoeic women with PCOS may develop endometrial hyperplasia and later carcinoma. It is good practice to recommend treatment with progestogens to induce a withdrawal bleed at least every three to four months.
The possible association of PCOS (at least in its most severe manifestation as Stein-Leventhal syndrome) with risk of postmenopausal breast cancer has also been investigated in a large cohort study. 27 Women with Stein-Leventhal syndrome were not more likely to develop breast cancer than non-PCOS controls (RR 1.2; 95% CI 0.7-2.0), suggesting that postmenopausal women with PCOS do not require surveillance over and above that offered by the National Breast Screening Programme.
Strategies for reduction of risk
Exercise and weight control
The impact of exercise and reduction in body mass by hypocaloric dieting on ovarian function in PCOS is well characterised. Adoption of simple methods for reduction of body fat and 28 The demonstration that improvement in diet and exercise in obese young women with PCOS is accompanied by a normalisation in glucose metabolism suggests that lifestyle alteration will reduce the likelihood of developing type II diabetes later in life. 29 There is no clear evidence of an effect of diet or exercise on the long-term health of women with PCOS who have normal body habitus, although it seems prudent to advise such patients to maintain their body weight within the normal range.
C
Evidence level IIb Evidence level III Evidence level IIa B B improvement in physical fitness will result in resumption of ovulation and increase in fertility in a high proportion of anovulatory obese PCOS women.
Drug therapy
The demonstration of the long-term health consequences of PCOS has been accompanied by renewed interest in the use of drugs, particularly 'insulin-sensitising agents' such as metformin and troglitazone, to reduce insulin resistance and thereby reduce risk of developing diabetes and other metabolic sequelae. Both metformin 30, 31 and troglitazone 32, 33 have been shown to have beneficial short-term effects on both reproductive function and insulin resistance in non-diabetic women with PCOS. Anxieties concerning adverse effects of troglitazone on hepatic function have led to its withdrawal in UK, although newer insulin-sensitising agents are currently under development.
To date, there have been no published long-term studies on the effects of insulin-sensitising agents on polycystic ovary insulin resistance or on reduction in incidence of impaired glucose tolerance, type II diabetes or dyslipidaemia. Although many internet sites advise consideration of metformin in such circumstances, evidence for long-term safety and efficacy in non-diabetic patients with PCOS is lacking. Studies to date have only assessed the impact of insulin-sensitising agents in the short-term, and well-designed randomised controlled trials in this area are urgently needed.
Insulin-sensitising agents have not been licensed in the UK for use in nondiabetic patients. Nevertheless, a body of evidence has accumulated demonstrating both their safety and, in some studies, efficacy in the management of short-term complications of PCOS, particularly anovulation. Long-term use of insulin-sensitising agents for avoidance of metabolic complications of PCOS cannot as yet be recommended.
Surgery
Anovulation associated with PCOS has long been known to be amenable to surgical treatment, and a recent long-term cohort study up to 20 years after laparoscopic ovarian electrocautery has shown persistence of ovulation and normalisation of serum androgens and SHBG over many years in over 60% of subjects. 34 Insulin resistance and serum lipids were not assessed, but women with PCOS treated with ovarian diathermy for reproductive reasons might obtain long-term benefit over and above resumption of ovulation and menses. The long-term benefits of ovarian drilling, including alterations in endocrine profile, have recently been confirmed in a second publication. 35 However, at present, the risks of surgery do not justify recommendation of this treatment purely in an attempt to ameliorate the chances of developing diabetes or coronary artery disease in later life.
Screening young PCOS patients for long-term health risk
Epidemiological and experimental studies suggest that young women with PCOS are at increased risk of developing type II diabetes and disorders secondary to hyperlipidaemia, when compared with women who do not have PCOS. 18 However, evidence that these metabolic complications lead to an increased risk of early death is lacking. A retrospective cohort study has shown an increased prevalence of non-fatal cardiovascular disease and cardiovascular disease risk factors among women with PCOS. 36 In order to encourage compliance with a regimen of diet and exercise designed to maintain a normal body habitus, it seems reasonable to offer measurement of glucose in a fasting blood sample, along with measurement of lipids and triglycerides. A 75-gram oral B Evidence level IV glucose tolerance test with measurement of glucose at 0 and 2 hours (with consideration of including measurement of insulin concentrations) should be performed if fasting glucose is elevated at the time of diagnosis, 37 and may be advisable even if fasting glucose is normal. This advice is particularly relevant for obese patients with PCOS (body mass index greater than 30 for white race groups, with adjustment for other ethnic groups) and if there is a family history of diabetes or heart disease. However, adverse lipid profiles are seen even in 'thin' women with PCOS and and non-obese women with PCOS might also benefit from this information. 8, 14, 38 Women with PCOS who are found to have abnormal glucose tolerance, hyperinsulinemia or an adverse lipid profile should be referred appropriately for further advice and management.
No clear consensus has yet emerged concerning regular screening of women with PCOS for later development of diabetes and dyslipidemia,13,37 but obese women with a strong family history of cardiac disease or diabetes should be assessed regularly in a general practice or hospital outpatient setting. Local protocols should be developed and adapted as new evidence emerges.
APPENDIX
Clinical guidelines are: 'systematically developed statements which assist clinicians and patients in making decisions about appropriate treatment for specific conditions'. Each guideline is systematically developed using a standardised methodology. Exact details of this process can be found in Clinical Governance Advice No. 1: Guidance for the Development of RCOG Green-top Guidelines (available on the RCOG website at www.rcog.org.uk/clingov1). These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.
The evidence used in this guideline was graded using the scheme below and the recommendations formulated in a similar fashion with a standardised grading scheme.
Classification of evidence levels
Ia
Evidence obtained from meta-analysis of randomised controlled trials.
Ib
Evidence obtained from at least one randomised controlled trial. IIa Evidence obtained from at least one well-designed controlled study without randomisation. IIb Evidence obtained from at least one other type of well-designed quasi-experimental study. III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies. IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities.
Grades of recommendations
Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. 
